View metadata, citation and similar papers at core.ac.uk
brought to you by CORE
provided by Apollo

Diabetes mellitus and pancreatitis in dogs and cats – cause or effect?

SUMMARY

Diabetes mellitus (DM) and pancreatitis are two distinct diseases encountered commonly in small animal practice. Whilst the clinical signs of DM are usually unmistakeable, a firm diagnosis of pancreatitis can prove more elusive, as clinical signs are often variable. Over the past 10-15 years, despite the fact that the clinical signs of DM are remarkably consistent, it has become more apparent that the underlying pathology of DM in dogs and cats is heterogeneous, with exocrine pancreatic inflammation accompanying DM in a number of cases. However, the question remains as to whether the DM causes the pancreatitis or whether, conversely, the pancreatitis leads to DM - as there is evidence to support both scenarios. The concurrence of DM and pancreatitis has clinical implications for case management as such cases may follow a more difficult clinical course, with their glycaemic control being 'brittle' as a result of variation in the degree of pancreatic inflammation. Problems may also arise if abdominal pain or vomiting lead to anorexia. In addition, diabetic cases with pancreatitis are at risk of developing exocrine pancreatic insufficiency in the following months to years, which can complicate their management further.

INTRODUCTION

Pancreatitis and diabetes mellitus (DM) have been reported to occur concurrently in many species – ranging from humans (Larsen 1993), to dogs and cats (Hess and others 2000, Rand and others 2004), to a cow (Doherty and others 1998), a horse (Jeffrey 1968) and a sea lion (Meegan and others 2008). It is more than 100 years since the relationship between DM and pancreatitis was first described in the scientific literature (Opie 1901), yet it is still not clear which disease occurs first i.e. whether the

DM is a *cause* or a *consequence* of the pancreatic inflammation (Cook and others 1993, Zini and others 2010b). The aim of this review is to examine current knowledge of the pathogenesis of both DM and pancreatitis in cats and dogs, and to examine the evidence for DM leading to pancreatitis or *vice versa*. There is of course a third option, where the two diseases are simply concurrent co-incidentally, but the close anatomical relationship between the exocrine and endocrine tissues of the pancreas and the increased prevalence of pancreatitis in diabetic dogs (Hess and others 2000) and cats (Goossens and others 1998) compared to that in the non-diabetic canine and feline population would suggest that this is not the case.

Prior to attempting to evaluate causality in the relationship between DM and pancreatitis, it is first necessary to review what is known about the pathogenesis of the two conditions.

Pathogenesis of Canine DM

Canine DM is usually the result of insulin deficiency and a classification scheme has been described, illustrated in Table 1 (Catchpole and others 2005, Catchpole and others 2008). There are several classification schemes for human DM, but in broad terms, type 1 and type 2 DM are the most commonly recognised conditions. Type 1 DM, accounting for approximately 10% of human diabetic patients, is characterised by pancreatic beta cell autoimmunity, insulin deficiency and disease onset in childhood. In contrast, type 2 disease is commonly associated with obesity and is characterised by insulin resistance and onset during adulthood. As it is a disease of insulin deficiency, canine DM historically has been regarded as most similar to human type 1 DM.

The prevalence of canine DM in the UK is estimated at 0.32% (Davison and others 2005). In some cases insulin deficiency may be preceded by a phase of insulin resistance, but by the time of diagnosis, most dogs are unable to synthesise and secrete adequate amounts of endogenous insulin from the pancreatic beta cells in response to hyperglycaemia (Hoenig 2002, Rand and others 2004). Certain breeds are predisposed to the disease such as the Samoyed, Tibetan terrier and Cairn terrier

whereas others have a reduced risk such as the boxer, German shepherd dog and the golden retriever (Davison and others 2005). Many genetic variants have been associated with risk of DM in the dog, mostly within genes involving innate and adaptive immune responses (Kennedy and others 2006, Short and others 2009, Catchpole and others 2012). The fact that many reported diabetes-associated genetic variants are breed-specific highlights the possibility that the underlying mechanism(s) for the development of DM may differ between breeds.

A small number of cases of canine DM are diagnosed in young animals less than 6 months of age (Atkins and others 1979), and these are considered to be congenital in origin. Usually these cases do not suffer exocrine pancreatic disease so the pathology is likely to be beta-cell specific.

The insulin resistance that precedes diagnosis in an estimated 20-40% of adult canine DM cases may be caused by exogenous corticosteroid or progestagen treatment or endocrinopathies such as hyperadrenocorticism (Hess and others 2000). In addition, by a physiological process unique to the canine species, insulin resistance severe enough to culminate in DM may arise in the progesterone-dominated phase of dioestrus in entire females, during which growth hormone production by the mammary glands also contributes to poor glucose tolerance and dioestrus DM (Selman and others 1994, Poppl and others 2012).

Chronic hyperglycaemia in dogs has been shown to result in permanent beta cell damage (Imamura and others 1988), which is likely to contribute to the fact that almost without exception, diabetic dogs are fully dependent on insulin from the time of diagnosis. Whilst some studies imply that obesity may also contribute to insulin resistance in dogs (Mattheeuws and others 1984, Tvarijonaviciute and others 2012), the evidence for obesity being a risk factor in the development of canine DM is limited (Klinkenberg and others 2006). It is interesting to note, however, in the context of this review, that obesity is also a risk factor for pancreatitis in dogs, and that elevated post prandial triglyceride concentrations have been associated with increased markers of pancreatic

73 inflammation in obese dogs (Verkest and others 2012) and miniature schnauzers (Xenoulis and
74 others 2010) .

75 However, not every dog that experiences insulin resistance develops hyperglycaemia. It is possible
76 that breed-related differences in beta cell pancreatic reserve exist and it is also possible that
77 hyperglycaemia may only develop in such circumstances in those dogs who have previously
78 experienced a primary beta cell insult.

79 Diabetes mellitus associated with pancreatitis may account for 28-40% of cases of canine DM
80 (Alejandro and others 1988, Hess and others 2000). Clinical signs may not differ greatly from other
81 forms of DM, although it is possible that classic signs of acute pancreatitis (AP) may be seen in
82 addition to the characteristic polyuria, polydipsia, glycosuria and weight loss DM signs. For example
83 some diabetic dogs with concurrent pancreatitis may present with abdominal pain, vomiting and
84 anorexia – which is in particular contrast to the usually voracious appetite of diabetic cases. It is also
85 of note that a recent study suggested that 41% of canine cases with diabetic ketoacidosis (DKA) have
86 biochemical and / or clinical evidence of AP (Hume and others 2006), implying that one may
87 contribute to the other. Although awareness of pancreatitis in canine DM is increasing, in some DM
88 cases pancreatitis may still go unrecognised, especially those with concurrent DKA. This is because
89 clinical signs of pancreatitis can be subtle and non-specific, especially in its chronic form and may be
90 attributed by the clinician to the DKA itself.

91 The remaining cases of canine DM are suspected to be associated with beta cell autoimmunity,
92 similar to Type 1 DM in humans (Elie and Hoenig 1995). Serological evidence of reactivity to
93 pancreatic autoantigens (Haines and Penhale 1985, Hoenig and Dawe 1992) such as GAD65, IA-2
94 (Davison and others 2008b) and proinsulin (Davison and others 2011) has been documented in a
95 number of recently diagnosed canine diabetic cases, but more than 50% of diabetic dogs studied
96 were negative for autoantibodies, reinforcing the heterogeneous nature of the underlying
97 pathogenesis of canine DM. The 'trigger' for autoimmunity in both humans and dogs is not clear,

although many genetic and environmental factors are known to contribute to autoimmune disease. Although exocrine pancreatic inflammation is not a common feature or trigger of human type 1 disease, in dogs it has been proposed that pancreatitis may lead to DM via 'bystander' beta cell damage, resulting in the release of protein antigens usually 'hidden' from the immune system and the initiation of beta cell autoreactivity (Hoenig 2002).

Autoimmune (Type 1) DM in humans is characterised by lymphocytic infiltration of pancreatic islets (insulitis), which is not a common feature of canine DM, although insulitis was reported in pancreatic biopsies of 6 of 18 diabetic dogs in one study (Alejandro and others 1988). It is unfortunate that large scale pathological studies of canine pancreas at the time of diagnosis are lacking, as such data might help to answer the 'cause or effect' question about DM. However, where data have been published, a mixed inflammatory picture in early disease is seen (Gepts and Toussaint 1967), followed by complete islet destruction as DM progresses. In the context of this review, it is interesting to note that in one study, 5 of the 18 diabetic dogs where the pancreas was examined were reported to have generalised pancreatic inflammation, affecting both endocrine and exocrine tissue (Alejandro and others 1988).

Pathogenesis of Feline DM

Feline DM has an estimated UK prevalence of 1 in 230 cats (McCann and others 2007) and in contrast to canine DM is usually characterised by insulin resistance rather than absolute insulin deficiency (Rand and others 2004). The disease has a multifactorial aetiology which includes genetic factors and environmental influences such as obesity and physical inactivity (McCann and others 2007, Slingerland and others 2009, Backus and others 2010), but the exact underlying cause is unclear as not all obese cats become diabetic. Feline DM appears to be more common with increasing age, and certain breeds such as the Burmese cat are predisposed, emphasising the genetic component to risk (McCann and others 2007, Lederer and others 2009). The recent increase in prevalence, however, is likely to be related to environmental factors (Prahl and others 2007).

Other diseases can lead to DM in non-obese cats either directly via beta cell damage such as pancreatic neoplasia (Linderman and others 2012), and pancreatitis (Mansfield and Jones 2001b), or via insulin resistance e.g. acromegaly (Niessen 2010) or hyperadrenocorticism (Neiger and others 2004). In addition, overt DM may be triggered by drug therapy with pharmacological agents which antagonise insulin e.g. corticosteroids or progestagens.

Overt DM in cats usually results from a combination of impaired insulin secretion from the pancreatic beta cells in addition to peripheral insulin resistance (Rand and others 2004). Pancreatitis may contribute to both these aspects as the local environment may impact directly on beta cell function and in addition, inflammation is known to cause peripheral tissue insulin resistance (Shoelson and others 2006). Most cats are thought to undergo a pre-diabetic glucose-intolerant phase before the islets are unable to keep up with the extra demand for insulin created by insulin resistance in the tissues (Osto and others 2012).

Eighty to ninety five percent of feline DM cases have been classified as similar to human type 2 DM (Rand 1999, O'Brien 2002) based on clinical and histological findings. The term ‘glucose toxicity’ is used to describe the damage to pancreatic islets as the result of persistent hyperglycaemia (Rand 1999, Osto and others 2012) – and although this may result in permanent damage or death of the cell, this typically does not lead to an inflammatory response because cell death occurs by apoptosis (programmed cell death) rather than necrosis (Majno and Joris 1995).

The phenomenon of a remission or ‘honeymoon’ phase once a diabetic cat is treated with insulin occurs because, in contrast to dogs, who are unlikely to have any islets left at the time of diagnosis, feline diabetic cases usually have impaired islet function rather than absolute loss in beta cell numbers at diagnosis. Hence diabetic remission, where it occurs, is the result of beta cell recovery as the blood glucose is controlled by exogenous insulin (Rand and Marshall 2005). Recent studies suggest that this may be facilitated by a restricted carbohydrate diet (Kirk 2006, Coradini and others 2011) and intensive insulin therapy to maintain blood glucose concentration within tight limits.

Sustained experimental hyperglycaemia in cats (but not hyperlipidaemia) leads to early, severe beta cell dysfunction and beta cell loss via apoptosis (Zini and others 2009). This means that if irreversible beta cell damage has occurred before or during the hyperglycaemic phase in a patient, apoptotic beta cell death will lead to failure of the patient to enter diabetic remission. It is not clear whether diabetic remission is less likely to be achieved in cats with concurrent pancreatitis (Zini and others 2010a), but being aware of the presence of this additional complication will allow pain relief and other treatment to be provided as necessary which is likely to improve the welfare of the patient.

Pathophysiology of acute and chronic pancreatitis in dogs

Pancreatitis specifically describes inflammation of the exocrine tissues of the pancreas, but in contrast to humans, no universally accepted classification system exists in veterinary medicine (Ruaux and Atwell 1998, Newman and others 2006, Mansfield 2012a, Watson 2012). Clinically, the presentation may be acute, with some cases suffering recurrent acute episodes, or chronic, potentially resulting in pancreatic fibrosis. It is therefore possible that AP might cause transient insulin deficiency, whereas chronic pancreatitis (CP) could lead to permanent loss of beta cells.

The exocrine tissue comprises 95% of the pancreas and surrounds the endocrine tissue, which is arranged in the islets of Langerhans, composed of insulin-secreting beta cells, glucagon-secreting alpha cells and somatostatin-secreting delta cells. Although pancreatitis is common, lesions in the exocrine pancreas evident at a histological level are much more frequent than gross lesions in dogs (Newman and others 2006). It must also be remembered that much of the current knowledge of the pathophysiology of pancreatitis in dogs and cats is extrapolated from experimental studies, so a degree of caution is required in its interpretation.

Several ‘safeguards’ are in place to ensure that the highly damaging pancreatic enzymes synthesised and secreted by the exocrine cells do not damage the delicate pancreatic tissues in humans and other species (Mansfield 2012b), such as the storage of enzymes as inactive zymogen precursors

(Rinderknecht 1986), physical separation of the stored enzyme from the rest of the cell in granules, as well as pancreas-derived secretory trypsin inhibitors and circulating anti-proteases in the blood to prevent the inappropriate conversion of trypsinogen to trypsin (Laskowski and Kato 1980).

These safeguards fail in pancreatitis, allowing activation of trypsin and other proteases within the pancreas itself. This is thought to be a key step in the initiation of the disease, leading to a cascade of local damage and inflammation (Mansfield 2012b).

As previously mentioned, when pancreatic cells die by apoptosis (programmed cell death), there is little inflammatory response (Majno and Joris 1995). In contrast, however, where pancreatic necrosis occurs following protease exposure, a much more significant and damaging 'cytokine storm' may follow (Makhija and Kingsnorth 2002). In AP, the cytokines IL-1, IL-6 and TNF-alpha all contribute to the inflammatory response, as well as encouraging recruitment of white blood cells such as monocytes to the area.

A single, isolated, acute pancreatic inflammatory event is not likely to cause DM (although this has occasionally been reported in humans (Raman and others 2011)), but the endocrine tissue is more likely to become more seriously affected if inflammation and / or clinical signs persist as CP. The prevalence of CP in the UK canine population has been estimated at 34% (Watson and others 2007), with a high proportion of cases with chronic pancreatic inflammation documented at necropsy showing no associated clinical signs in life. A recent study of 61 cases and 100 controls in the USA suggested that dogs with clinical CP have significantly higher histological scores for pancreatic necrosis and peri-pancreatic fat necrosis (usually more associated with acute disease) than dogs with incidental CP, implying they may in fact have acute-on-chronic pancreatitis (Bostrom and others 2013). This supports the necrosis-fibrosis theory of CP which suggests that irreversible damage is caused by repeated acute insults to the pancreatic tissue.

Certain breeds appear to be predisposed to AP including spaniels, terriers, dachshunds and poodles. Recent work to examine the breed-related prevalence of CP in post mortem pancreata from first opinion practice in the UK suggested that histological evidence of CP in dogs is present in approximately 34% of cadavers, with Cavalier King Charles spaniels (CKCS), collies and boxers being over represented (Watson and others 2007). Intriguingly, boxers are under-represented in canine diabetic cohorts (Fall and others 2007).

Definitive diagnosis and classification of pancreatitis has been discussed elsewhere (Cordner and others 2010), Mansfield and others 2012, (Watson 2012). A presumptive non-invasive diagnosis is usually made using a combination of history, physical examination and clinical signs, in combination with measurement of canine pancreatic lipase immunoreactivity (cPLI) (Mansfield and others 2012) and / or ultrasonographic examination of the pancreas.

Pathophysiology of acute and chronic pancreatitis in cats

Similar to pancreatitis in dogs, the aetiology of pancreatitis in cats is also only partially understood (Xenoulis and Steiner 2008), but what is known of the pathophysiology has been well reviewed (Bazelle and Watson 2014). The basic protective mechanisms and anatomy of the pancreas are similar to those described in the dog (Mansfield and Jones 2001a). However, the diagnosis of feline pancreatitis can be even more challenging than in dogs because clinical signs may be very mild, non-specific and remain unnoticed by the owner (Xenoulis and Steiner 2008), such as partial anorexia or lethargy (Washabau 2001). This makes it difficult to assess its prevalence in the diabetic and non-diabetic population. Early studies suggested a prevalence of less than 3% (Steiner and Williams 1999) but more recent histopathological work implies that the prevalence of pancreatic inflammation in cats is much higher than this – 67% in animals with clinical signs and 45% in clinically healthy cats, with the majority of these cases having chronic rather than acute inflammatory infiltrates (De Cock and others 2007). Within the diabetic cat population, the prevalence of pancreatic inflammation may be even higher still – with evidence of pancreatitis at post mortem examination being described

in 19 out of 27 diabetic cats examined (Goossens and others 1998). The histopathological features of feline pancreatitis have been extensively reviewed (Mansfield and Jones 2001a) and vary in severity and chronicity. Pancreatitis in cats may also be associated with cholangiohepatitis and inflammatory bowel disease (Caney 2013).

As in dogs, the underlying cause of pancreatitis in cats is not clear, but genetics, infection (e.g. viral, parasitic), trauma and the presence of other common inflammatory conditions may all contribute to risk (Xenoulis and Steiner 2008). Diagnosis may be especially challenging in cats as already described, but a combination of history, clinical examination, diagnostic imaging and feline pancreas specific lipase (fPLI) measurement is recommended (Forman and others 2004, Xenoulis and Steiner 2008). As in dogs, CP in cats may eventually result in exocrine pancreatic insufficiency as the enzyme-producing cells are slowly replaced by fibrous tissue (Steiner and Williams 1999).

The relationship between exocrine pancreatic inflammation and DM in human medicine

As illustrated above, canine and feline DM have similar clinical signs but different underlying pathophysiology. It is therefore conceivable that the role of pancreatitis in each disease will be different. In dogs, the closest human parallel is type 1 DM and in cats the closest human parallel is type 2 DM, so the contribution of pancreatitis to both these diseases, and in contrast the potential contribution of both these diseases to pancreatitis, should be considered. However, there is very little published evidence of type 1 DM and acute (or chronic) pancreatitis co-existing in human medicine. This may be because type 1 DM usually occurs in young children (Hummel and others 2012) and in this age group pancreatitis is usually confined to genetic or traumatic causes, meaning that the majority of human diabetes – pancreatitis studies relate to type 2 DM. There is clear evidence that patients with longstanding type 1 DM develop pancreatic atrophy (Williams and others 2012), but to the author's knowledge, there are no clear human studies linking type 1 DM to risk of pancreatitis later in life.

Not surprisingly, human pancreatitis has many underlying causes, with acute disease commonly being associated with toxaemia, gallstones, trauma, medication or infection. One difference between humans and veterinary species is that bacterial translocation from the gut is a well-recognised and important source of infection in human AP, and may result in pancreatic abscessation (Schmid and others 1999). In human AP, clinical signs include severe abdominal pain, fever, nausea, vomiting or dehydration and in those cases where pancreatic necrosis occurs, the disease may be fatal (Cruz-Santamaria and others 2012).

The most common cause of CP in humans is chronic alcohol consumption but genetic predisposition, autoimmune disease, or other diseases such as cystic fibrosis may also chronically impede exocrine pancreatic function and lead to pancreatic inflammation. Chronic pancreatitis shows similar clinical signs to acute disease but they are generally less severe and more prolonged. It is of particular note that in human type 2 DM, the risk of CP is two to three times higher than that in healthy subjects (Girman and others 2010) and a recent meta-analysis indicated that type 2 diabetic patients are also at increased risk of AP (Yang and others 2013).

This raises the question of why human type 2 DM patients are prone to pancreatitis – does the diabetic state itself contribute to the onset of pancreatic inflammation? This possibility is raised by a meta-analysis in which diabetic individuals had a 92% increased risk of development of CP, independent of other risk factors such as alcohol use, gallstones and hyperlipidaemia (Xue and others 2012). Similarly in AP, a meta-analysis reported that insulin resistance and hyperglycaemia are important factors in the susceptibility of diabetic individuals to AP (Solanki and others 2012). It is also of potential relevance that human patients with DM are at a greater risk of particularly severe AP, even if the DM was not originally associated with pancreatitis at diagnosis (Shen and others 2012). Experimental rodent models of pancreatitis and DM suggest that the presence of hyperglycaemia can exacerbate AP and suppress regeneration of exocrine tissue (Zechner and others

2012). This implies an important clinical point - that poor glycaemic control may contribute to the severity of AP and aggravate the progression of the disease.

Although the studies mentioned above highlight the increased risk for pancreatitis in diabetic patients, the majority of the published evidence points to pancreatitis preceding the DM in humans i.e. the DM is secondary to the pancreatitis rather than the DM causing pancreatic inflammation (Kazumi and others 1983, Jap and others 1992, Cavallini and others 1993, Larsen 1993). A recent meta-analysis suggested that following an episode of AP, a patient has a two-fold increased risk of developing DM within 5 years (Das and others 2014). This type of DM is classified as neither type 1 nor type 2 DM, but a separate category of “other specific types of DM”.

Diabetes mellitus in human patients with CP is more likely to be found later in the course of the exocrine pancreatic disease (Singh and others 2012), and similar to canine and feline cases, CP in humans may ultimately result in malabsorption due to pancreatic insufficiency. This timecourse is also similar to an obese rodent model of pancreatitis, in which DM develops later during the course of the disease. It is of particular interest in this model that the pancreatitis can be made less severe and the onset of DM delayed by dietary restriction (Akimoto and others 2010).

As already discussed for dogs and cats, the exact mechanism by which CP results in DM is likely to be complex in humans. Studies of cytokine concentrations in pancreatic tissues from CP patients by flow cytometry demonstrate increased interferon gamma in both diabetic and non-diabetic patients, a cytokine which has been shown to impede beta cell function and therefore may play a role in DM associated with CP (Pavan Kumar and others 2012). It is also apparent that patients with concurrent type 2 DM and CP have an increased risk of developing pancreatic cancer (Brodovicz and others 2012), although no similar correlation has been reported in dogs or cats.

A more rare condition in humans, called Autoimmune Pancreatitis (AIP) is characterised radiologically by enlargement of the pancreas, narrowing of the pancreatic duct, lymphoplasmacytic

pancreatic infiltrate and classically an elevation of serum IgG4 levels (Kamisawa and others 2010). This disease is commonly associated with insulin-dependent DM in adults (Ito and others 2011) and tends to be very responsive to steroid treatment. These patients rarely have the autoantibodies to islet antigens that characterise classical type 1 DM, although pancreatic histology suggests cellular islet infiltrates and reduced numbers of beta cells. The classic autoantigens in AIP are lactoferrins and carbonic anhydrase II (Hardt and others 2008). The pathophysiology of the DM seen in AIP has not been fully elucidated but is not thought to be related to non-specific collateral damage from the pancreatic inflammatory process, but rather a specific immunological effect, thought to be triggered by the pancreatitis (Miyamoto and others 2012). This would therefore again make the pancreatitis a cause rather than an effect of the DM and offers an alternative mechanism for immune-mediated islet destruction. At present, however, IgG4 measurement is not routinely performed in veterinary medicine, so a companion animal counterpart of AIP has not been identified, although studies are ongoing and it is possible that certain types of breed-related DM may share pathophysiological features with AIP.

The relationship between pancreatitis and DM in dogs

In a study of 80 dogs with severe AP, 29 dogs had concurrent DM (Papa and others 2011), making the prevalence of DM much higher in this population than in dogs without AP. In a recent UK retrospective study of DM in first opinion practice (Mattin and others 2014), diabetic dogs diagnosed with pancreatitis also had a higher hazard of death. Having reviewed the underlying causes of both diseases, and the relationship between these conditions in humans, the question remains, does canine pancreatitis cause DM or can canine DM result in pancreatitis? The intuitive answer is that pancreatitis is likely to occur first, with the beta cells succumbing to bystander damage, either by non-specific inflammation or the triggering of an autoimmune process and epitope spreading. However, the increased risk of pancreatitis in human diabetic patients also suggests that pancreatitis

could theoretically be a *consequence* of DM, so it may be the case that both diseases may have a negative impact on each other.

It is possible too that a more broad, over-arching mechanism may be at work. In another recent study, canine CP cases were significantly more likely to have an endocrine disease than dogs without pancreatitis, specifically DM or hypothyroidism (Bostrom and others 2013). It is therefore possible that the mechanisms for pancreatitis development in both hypothyroidism and DM are similar, implying that endocrine disease may be contributing to the initiation of the pancreatic inflammation. One such risk factor, shared between DM and hypothyroidism, may be the high cholesterol resulting from the endocrinopathy acting as a trigger for pancreatitis, as hyperlipidaemia has been shown to cause pancreatitis in humans (Tsuang and others 2009) and dogs (Hess and others 1999). However, it must also be remembered that in dogs, as in humans, there are shared genetic factors for DM and hypothyroidism so it is also possible that these may be shared with other genetic risk factors for pancreatitis. Sharing of genetic risk variants does not necessarily imply that one disease causes the other.

Is there any evidence at the cellular or molecular level that DM may trigger pancreatitis in dogs? Although the cytokine milieu in human and canine pancreatitis has been investigated (discussed earlier), very little is known about the local cytokine environment in the pancreatic islets in canine DM. However, despite the lack of local measurements, some circulating cytokine profiles have been reported in a study of healthy dogs, dogs with DM and dogs with DKA. The cytokines IL-18 and GM-CSF were elevated in DKA dogs before treatment compared to after successful treatment, and pro-inflammatory factors CXCL8 and MCP-1 were significantly higher in dogs with DM compared to controls (O'Neill and others 2012). However, 7 of the 9 dogs with DKA in this study also had pancreatitis, and as IL-18 is a pro-inflammatory cytokine associated with pancreatitis in humans it is difficult to know if the presence of this cytokine is a cause or consequence of the pancreatitis. Nonetheless, CXCL8 and MCP-1 are both associated with inflammation, so have the potential to

342 contribute to pancreatitis. A more recent study of alterations in innate immunity in dogs associated
343 with DM also suggested that white blood cells from diabetic cases produce more pro-inflammatory
344 cytokines in response to stimulation and hypothesised that this may predispose diabetic dogs to
345 infectious and inflammatory complications (DeClue and others 2012).

346 Another theoretical trigger for pancreatitis which may be associated with DM in dogs is the potential
347 for the presence of circulating autoantibodies to pancreatic proteins or anti-insulin antibodies
348 induced by treatment (Davison and others 2003, Davison and others 2008a) to form immune
349 complexes in the pancreas. However, this is most likely an academic concern as it has not been
350 proven in practice. Cats do not appear to suffer from autoimmune pancreatitis and nor do they
351 commonly make antibodies to exogenous insulin so this mechanism appears even less likely to occur
352 in this species (Hoenig and others 2000).

353 Another particular challenge in establishing which disease occurs first relates to the fact that one
354 condition may be clinically silent e.g. CP. In a study of 14 confirmed canine cases of CP, the pancreas
355 only appeared 'abnormal' on 56% of ultrasound examinations and the sensitivity of cPLI when
356 combined with amylase and lipase measurement was 44 to 67% when using a low cut off value.
357 (Watson and others 2010). At present, it is not routine to test the glucose tolerance of all cases with
358 AP or CP or to test pancreatic inflammatory markers in all newly diagnosed canine diabetic cases.
359 Nor, of course are pancreatic biopsies routine in diabetic cases. However, some work has been
360 undertaken to try to establish the prevalence of defective beta cell function amongst pancreatitis
361 cases which gives some insight into the order in which the diseases may arise.

362 Watson and Herrtage (2004) used a glucagon stimulation test to evaluate endocrine pancreatic
363 reserve in canine cases with clinical pancreatitis. By measuring the insulin and glucose response
364 following an intravenous glucagon dose, a functional defect in endocrine pancreatic function was
365 demonstrated in 5 of 6 dogs with pancreatitis, implying that inflammation can impair insulin
366 secretion from beta cells. This suggests that in cases where the two diseases are concurrent,

pancreatic inflammation may precede DM in dogs. A similar timeline was seen in a small case series of 4 dogs with EPI secondary to CP. Two of these dogs developed DM, and this happened after the diagnosis of CP but before the diagnosis of EPI (Watson 2003). This suggests an order of events beginning with pancreatitis, moving on to DM and culminating in pancreatic fibrosis and EPI, at least in some dogs. This mirrors the findings of recent human studies which suggest that in cases where DM develops secondary to CP, islet dysfunction occurs first due to the local inflammatory milieu but clinical DM does not manifest until later, when fibrosis causes islet destruction (Sasikala and others 2012).

The relationship between pancreatitis and DM in cats

One recent study reported that 26 of 40 cats with naturally occurring DM were found to have elevated lipase concentration at the time of admission to a clinical facility (Zini and others 2010b). Although elevation in serum lipase is not perfectly sensitive or specific for a diagnosis of pancreatitis, this study appears to concur with a 1998 study in which 19 of 37 diabetic cats were shown to have evidence of pancreatic inflammation on post mortem examination (Goossens and others 1998). As the pathology of DM in cats relates to insulin resistance, which can be caused by a focus of inflammation within the body, it is not difficult to propose a causal role for pancreatitis in feline DM. If this is the case, similar mechanisms for islet cell damage to those discussed for canine pancreatitis may play a role.

However, to counter this argument, the biochemical states of hyperglycaemia and hyperlipidaemia, as seen in feline DM, have been shown to contribute to inflammatory responses in humans (Shoelson and others 2007) implying that the metabolic changes in DM may contribute to pancreatitis developing subsequently. As feline DM is considered to be similar to human type 2 DM, it is possible that diabetic cats are subject to the same increased risk for pancreatitis as already described for humans with type 2 DM. One experimental study, designed to investigate the relationship between hyperglycaemia, hyperlipidaemia and pancreatitis in cats reported that 10 days

of hyperglycaemia increased pancreatic neutrophils, but without causing pancreatic damage, a finding which was not seen in cats with experimentally induced hyperlipidaemia (Zini and others 2010b). This suggests that hyperglycaemia may play a role in predisposing to feline pancreatitis but other factors are also involved in the early stages of pancreatic inflammation.

It is also helpful to recognise recent work in human type 2 DM and metabolic syndrome has demonstrated that obesity and inflammation are directly linked (Shoelson and Goldfine 2009). Adipose tissue can have a significant influence on metabolism and the immune system via synthesis and secretion of chemical mediators such as adipokines and adipocytokines (Whitehead and others 2006). This pro-inflammatory environment can in turn lead to recruitment and activation of inflammatory cells and may also play a role in beta cell damage during hyperglycaemia via cytokines such as IL-6 and IL-1 beta. If this type of inflammation occurs in obese cats, within the pancreas, then it is certainly possible that it may act as a trigger for pancreatitis.

A biochemical marker of AP, although not 100% sensitive, feline pancreatic lipase immunoreactivity was found to be elevated in a different cohort of feline diabetic cases (Forcada and others 2008), and correlated with serum fructosamine concentration, which may also reflect the relationship between inflammation and insulin resistance.

Clinical implications of the relationship between pancreatitis and DM

Dogs: Based on the evidence presented here, the balance appears to be slightly in favour of pancreatitis preceding DM and hence in favour of the exocrine disease contributing to or triggering the endocrine disease. It is also clear, however, that there are multiple routes to lack of beta cell function in dogs and pancreatitis is only one potential causal factor. It is still theoretically possible that, at least in dogs, pancreatitis may develop in response to the hyperglycaemia or hyperlipidaemia associated with DM, a risk which may be even further exacerbated by the increased

potential for bacterial infection (DeClue and others 2012) and toxaemia in diabetic cases, but this is difficult to prove.

An important clinical observation is that where pancreatitis and DM do co-exist, the practitioner may be blinded to the presence of one of these conditions. The prevalence of the two diseases concurrently in dogs is remarkably high, and it is important to recognise AP or CP as it increases insulin resistance as well as being significantly correlated with risk of DKA. In addition there is the long term risk of intermittent 'flare-ups' of disease and the potential for glycaemic control to be complicated in future by the development of exocrine pancreatic insufficiency.

Although pancreatitis can be a difficult diagnosis to make clinically, for the reasons outlined above, in the author's opinion, serious consideration should be given to evaluating every diabetic dog, particularly those who are newly diagnosed or unstable, for exocrine pancreatic disease, for example by measurement of cPLI. Whilst management of pancreatitis may appear fairly non-specific, - being based on nutritional support, low fat food, intravenous fluid therapy and analgesia, the *knowledge* that a diabetic dog has accompanying exocrine pancreatic inflammation can make a further significant contribution to the clinical management and prognosis, allowing the owner and veterinary surgeon to make better informed decisions, improving the animal's quality of life.

In contrast, however, there is insufficient evidence at present to recommend a glucagon stimulation test to evaluate endocrine function in every animal with pancreatitis, but it is still important that cases that are suspected to have pancreatitis should be regularly examined and owners warned of the potential risks of DM in the future.

Cats: The relationship between obesity / inactivity and DM in cats is undeniable, so regardless of co-existing pancreatitis, weight loss and increased activity, plus an appropriate diet are the most important factors in helping to prevent many cases of DM in cats. As discussed however, there is clearly also an important relationship between insulin resistance and pancreatitis in cats, in which

439 the pancreatic exocrine tissue inflammation may even be initiated or exacerbated by
440 hyperglycaemia in some cases. It is therefore important to consider the possibility of pancreatic
441 inflammation in all diabetic cats, even if they have no history of AP, because hyperglycaemia
442 resulting from obesity, acromegaly, inflammation or exogenous drug treatment has the potential to
443 contribute to the development of exocrine pancreatic inflammation.

444 Where a diagnosis of pancreatitis pre-dates documented hyperglycaemia, it appears likely that
445 pancreatitis predisposes to the demise of beta cells and contributes to peripheral insulin resistance,
446 precipitating DM in genetically susceptibly or obese cats. The same principles discussed for dogs
447 therefore also apply to cats, i.e. ideally the clinician should be consciously aware of *both* diseases,
448 and should consider testing newly diagnosed diabetic cats for pancreatitis, especially because clinical
449 signs may be so subtle and unregulated pancreatic inflammation may have a dramatic and negative
450 impact on clinical outcome. This is especially true if an intensive protocol to achieve DM remission is
451 being undertaken, as active pancreatic inflammation and its associated clinical signs, however
452 subtle, may compromise the effectiveness of this approach.

453 **CONCLUSIONS:**

454 Diabetes mellitus and pancreatitis are both complex diseases, showing many species-specific
455 features in dogs, cats and humans. As the endocrine and exocrine tissues of the pancreas are so
456 interlinked, it is not surprising that damage to one or the other has an impact on the surrounding
457 tissues. The main conclusion that can be drawn is that whilst the most common direction of
458 progression may be that DM occurs secondary to pancreatitis, the two disease may still be seen in
459 the 'reverse order' in certain circumstances.

460 Additionally, DM and pancreatitis may arise by a number of mechanisms but there are particular
461 environmental triggers and genetic pre-dispositions which make this more likely. Figure 1 illustrates
462 the 'circular argument' of cause and effect, including putative (but not necessarily proven) factors

463 from each of the two diseases which could increase the risk of the second disease developing. The
464 most important message is that clinicians continue to remain aware of the potential for both
465 diseases to co-exist. The benefits to the diabetic patient when a serious complication is recognised
466 and treated, despite it having potentially only subtle clinical signs, will be just as important whether
467 or not the pancreatitis has arisen as a cause or consequence of the DM.

468

469

References:

T. Akimoto, M. Terada, A. Shimizu, N. Sawai & H. Ozawa (2010) The influence of dietary restriction on the development of diabetes and pancreatitis in female WBN/Kob-fatty rats. *Exp Anim* **59**, 623-630

R. Alejandro, E. C. Feldman, F. L. Shienvold & D. H. Mintz (1988) Advances in canine diabetes mellitus research: etiopathology and results of islet transplantation. *J Am Vet Med Assoc* **193**, 1050-1055

C. E. Atkins, J. R. Hill & R. K. Johnson (1979) Diabetes mellitus in the juvenile dog: a report of four cases. *J Am Vet Med Assoc* **175**, 362-368

R. C. Backus, N. J. Cave, V. K. Ganjam, J. B. Turner & V. C. Biourge (2010) Age and body weight effects on glucose and insulin tolerance in colony cats maintained since weaning on high dietary carbohydrate. *J Anim Physiol Anim Nutr (Berl)* **94**, e318-328

J. Bazelle & P. Watson (2014) Pancreatitis in cats: is it acute, is it chronic, is it significant? *J Feline Med Surg* **16**, 395-406

B. M. Bostrom, P. G. Xenoulis, S. J. Newman, R. R. Pool, G. T. Fosgate & J. M. Steiner (2013) Chronic pancreatitis in dogs: A retrospective study of clinical, clinicopathological, and histopathological findings in 61 cases. *Vet J* **195**, 73-79

K. G. Brodovicz, T. D. Kou, C. M. Alexander, E. A. O'Neill, S. S. Engel, C. J. Girman & B. J. Goldstein (2012) Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. *Diabetes Obes Metab* **9999**

S. M. Caney (2013) Pancreatitis and diabetes in cats. *Vet Clin North Am Small Anim Pract* **43**, 303-317

B. Catchpole, J. P. Adams, A. L. Holder, A. D. Short, W. E. Ollier & L. J. Kennedy (2012) Genetics of canine diabetes mellitus: Are the diabetes susceptibility genes identified in humans involved in breed susceptibility to diabetes mellitus in dogs? *Vet J*

B. Catchpole, L. J. Kennedy, L. J. Davison & W. E. Ollier (2008) Canine diabetes mellitus: from phenotype to genotype. *J Small Anim Pract* **49**, 4-10

B. Catchpole, J. M. Ristic, L. M. Fleeman & L. J. Davison (2005) Canine diabetes mellitus: can old dogs teach us new tricks? *Diabetologia* **48**, 1948-1956

G. Cavallini, B. Vaona, P. Bovo, M. Cigolini, L. Rigo, F. Rossi, E. Tasini, M. P. Brunori, V. Di Francesco & L. Frulloni (1993) Diabetes in chronic alcoholic pancreatitis. Role of residual beta cell function and insulin resistance. *Dig Dis Sci* **38**, 497-501

A. K. Cook, E. B. Breitschwerdt, J. F. Levine, S. E. Bunch & L. O. Linn (1993) Risk factors associated with acute pancreatitis in dogs: 101 cases (1985-1990). *J Am Vet Med Assoc* **203**, 673-679

M. Coradini, J. S. Rand, J. M. Morton & J. M. Rawlings (2011) Effects of two commercially available feline diets on glucose and insulin concentrations, insulin sensitivity and energetic efficiency of weight gain. *Br J Nutr* **106 Suppl 1**, S64-77

A. P. Cordner, P. J. Armstrong, S. J. Newman, R. Novo, L. C. Sharkey & C. Jessen Emeritus (2010) Effect of pancreatic tissue sampling on serum pancreatic enzyme levels in clinically healthy dogs. *J Vet Diagn Invest* **22**, 702-707

D. M. Cruz-Santamaria, C. Taxonera & M. Giner (2012) Update on pathogenesis and clinical management of acute pancreatitis. *World J Gastrointest Pathophysiol* **3**, 60-70

S. L. Das, P. P. Singh, A. R. Phillips, R. Murphy, J. A. Windsor & M. S. Petrov (2014) Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. *Gut* **63**, 818-831

L. J. Davison, M. E. Herrtage & B. Catchpole (2005) Study of 253 dogs in the United Kingdom with diabetes mellitus. *Vet Rec* **156**, 467-471

L. J. Davison, M. E. Herrtage & B. Catchpole (2011) Autoantibodies to recombinant canine proinsulin in canine diabetic patients. *Res Vet Sci* **91**, 58-63

L. J. Davison, J. M. Ristic, M. E. Herrtage, I. K. Ramsey & B. Catchpole (2003) Anti-insulin antibodies in dogs with naturally occurring diabetes mellitus. *Vet Immunol Immunopathol* **91**, 53-60

L. J. Davison, B. Walding, M. E. Herrtage & B. Catchpole (2008a) Anti-insulin antibodies in diabetic dogs before and after treatment with different insulin preparations. *J Vet Intern Med* **22**, 1317-1325

L. J. Davison, S. M. Weenink, M. R. Christie, M. E. Herrtage & B. Catchpole (2008b) Autoantibodies to GAD65 and IA-2 in canine diabetes mellitus. *Vet Immunol Immunopathol* **126**, 83-90
H. E. De Cock, M. A. Forman, T. B. Farver & S. L. Marks (2007) Prevalence and histopathologic characteristics of pancreatitis in cats. *Vet Pathol* **44**, 39-49
A. E. DeClue, J. Nickell, C. H. Chang & A. Honaker (2012) Upregulation of proinflammatory cytokine production in response to bacterial pathogen-associated molecular patterns in dogs with diabetes mellitus undergoing insulin therapy. *J Diabetes Sci Technol* **6**, 496-502
M. L. Doherty, A. M. Healy & W. J. Donnelly (1998) Diabetes mellitus associated with lymphocytic pancreatitis in a cow. *Vet Rec* **142**, 493
M. Elie & M. Hoenig (1995) Canine immune-mediated diabetes mellitus: a case report. *J Am Anim Hosp Assoc* **31**, 295-299
T. Fall, H. H. Hamlin, A. Hedhammar, O. Kampe & A. Egenvall (2007) Diabetes mellitus in a population of 180,000 insured dogs: incidence, survival, and breed distribution. *J Vet Intern Med* **21**, 1209-1216
Y. Forcada, A. J. German, P. J. Noble, J. M. Steiner, J. S. Suchodolski, P. Graham & L. Blackwood (2008) Determination of serum fPLI concentrations in cats with diabetes mellitus. *J Feline Med Surg* **10**, 480-487
M. A. Forman, S. L. Marks, H. E. De Cock, E. J. Hergesell, E. R. Wisner, T. W. Baker, P. H. Kass, J. M. Steiner & D. A. Williams (2004) Evaluation of serum feline pancreatic lipase immunoreactivity and helical computed tomography versus conventional testing for the diagnosis of feline pancreatitis. *J Vet Intern Med* **18**, 807-815
W. Gepts & D. Toussaint (1967) Spontaneous diabetes in dogs and cats. A pathological study. *Diabetologia* **3**, 249-265
C. J. Girman, T. D. Kou, B. Cai, C. M. Alexander, E. A. O'Neill, D. E. Williams-Herman & L. Katz (2010) Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. *Diabetes Obes Metab* **12**, 766-771
M. M. Goossens, R. W. Nelson, E. C. Feldman & S. M. Griffey (1998) Response to insulin treatment and survival in 104 cats with diabetes mellitus (1985-1995). *J Vet Intern Med* **12**, 1-6
D. M. Haines & W. J. Penhale (1985) Autoantibodies to pancreatic islet cells in canine diabetes mellitus. *Vet Immunol Immunopathol* **8**, 149-156
P. D. Hardt, N. Ewald, K. Brockling, S. Tanaka, T. Endo, H. U. Kloer, R. G. Bretzel, C. Jaeger, H. Shimura & T. Kobayashi (2008) Distinct autoantibodies against exocrine pancreatic antigens in European patients with type 1 diabetes mellitus and non-alcoholic chronic pancreatitis. *JOP* **9**, 683-689
R. S. Hess, P. H. Kass, F. S. Shofer, T. J. Van Winkle & R. J. Washabau (1999) Evaluation of risk factors for fatal acute pancreatitis in dogs. *J Am Vet Med Assoc* **214**, 46-51
R. S. Hess, H. M. Saunders, T. J. Van Winkle & C. R. Ward (2000) Concurrent disorders in dogs with diabetes mellitus: 221 cases (1993-1998). *J Am Vet Med Assoc* **217**, 1166-1173
M. Hoenig (2002) Comparative aspects of diabetes mellitus in dogs and cats. *Mol Cell Endocrinol* **197**, 221-229
M. Hoenig & D. L. Dawe (1992) A qualitative assay for beta cell antibodies. Preliminary results in dogs with diabetes mellitus. *Vet Immunol Immunopathol* **32**, 195-203
M. Hoenig, C. Reusch & M. E. Peterson (2000) Beta cell and insulin antibodies in treated and untreated diabetic cats. *Vet Immunol Immunopathol* **77**, 93-102
D. Z. Hume, K. J. Drobatz & R. S. Hess (2006) Outcome of dogs with diabetic ketoacidosis: 127 dogs (1993-2003). *J Vet Intern Med* **20**, 547-555
K. Hummel, K. K. McFann, J. Realsen, L. H. Messer, G. J. Klingensmith & H. P. Chase (2012) The increasing onset of type 1 diabetes in children. *J Pediatr* **161**, 652-657 e651
T. Imamura, M. Koffler, J. H. Helderman, D. Prince, R. Thirlby, L. Inman & R. H. Unger (1988) Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia. *Diabetes* **37**, 600-609

T. Ito, T. Nakamura, N. Fujimori, Y. Niina, H. Igarashi, T. Oono, M. Uchida, K. Kawabe, R. Takayanagi, I. Nishimori, M. Otsuki & T. Shimosegawa (2011) Characteristics of pancreatic diabetes in patients with autoimmune pancreatitis. *J Dig Dis* **12**, 210-216

T. S. Jap, C. F. Kwok & L. T. Ho (1992) Metabolic control and B cell function in patients with diabetes mellitus secondary to chronic pancreatitis. *Zhonghua Yi Xue Za Zhi (Taipei)* **49**, 141-146

J. R. Jeffrey (1968) Diabetes mellitus secondary to chronic pancreatitis in a pony. *J Am Vet Med Assoc* **153**, 1168-1175

T. Kamisawa, K. Takuma, N. Egawa, K. Tsuruta & T. Sasaki (2010) Autoimmune pancreatitis and IgG4-related sclerosing disease. *Nat Rev Gastroenterol Hepatol* **7**, 401-409

T. Kazumi, M. Ohya, I. Suehiro, N. Mizuno, S. Morita, M. Oimomi & S. Baba (1983) Diabetes mellitus secondary to idiopathic chronic calcifying pancreatitis in an adolescent woman. *Endocrinol Jpn* **30**, 261-266

L. J. Kennedy, L. J. Davison, A. Barnes, A. D. Short, N. Fretwell, C. A. Jones, A. C. Lee, W. E. Ollier & B. Catchpole (2006) Identification of susceptibility and protective major histocompatibility complex haplotypes in canine diabetes mellitus. *Tissue Antigens* **68**, 467-476

C. A. Kirk (2006) Feline diabetes mellitus: low carbohydrates versus high fiber? *Vet Clin North Am Small Anim Pract* **36**, 1297-1306, vii

H. Klinkenberg, M. H. Sallander & A. Hedhammar (2006) Feeding, exercise, and weight identified as risk factors in canine diabetes mellitus. *J Nutr* **136**, 1985S-1987S

S. Larsen (1993) Diabetes mellitus secondary to chronic pancreatitis. *Dan Med Bull* **40**, 153-162

M. Laskowski, Jr. & I. Kato (1980) Protein inhibitors of proteinases. *Annu Rev Biochem* **49**, 593-626

R. Lederer, J. S. Rand, N. N. Jonsson, I. P. Hughes & J. M. Morton (2009) Frequency of feline diabetes mellitus and breed predisposition in domestic cats in Australia. *Vet J* **179**, 254-258

M. J. Linderman, E. M. Brodsky, L. P. de Lorimier, C. A. Clifford & G. S. Post (2012) Feline exocrine pancreatic carcinoma: a retrospective study of 34 cases. *Vet Comp Oncol*

G. Majno & I. Joris (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. *Am J Pathol* **146**, 3-15

R. Makhija & A. N. Kingsnorth (2002) Cytokine storm in acute pancreatitis. *J Hepatobiliary Pancreat Surg* **9**, 401-410

C. Mansfield (2012a) Acute pancreatitis in dogs: advances in understanding, diagnostics, and treatment. *Top Companion Anim Med* **27**, 123-132

C. Mansfield (2012b) Pathophysiology of acute pancreatitis: potential application from experimental models and human medicine to dogs. *J Vet Intern Med* **26**, 875-887

C. S. Mansfield, G. A. Anderson & A. J. O'Hara (2012) Association between canine pancreatic-specific lipase and histologic exocrine pancreatic inflammation in dogs: assessing specificity. *J Vet Diagn Invest* **24**, 312-318

C. S. Mansfield & B. R. Jones (2001a) Review of feline pancreatitis part one: the normal feline pancreas, the pathophysiology, classification, prevalence and aetiologies of pancreatitis. *J Feline Med Surg* **3**, 117-124

C. S. Mansfield & B. R. Jones (2001b) Review of feline pancreatitis part two: clinical signs, diagnosis and treatment. *J Feline Med Surg* **3**, 125-132

D. Mattheeuws, R. Rottiers, J. J. Kaneko & A. Vermeulen (1984) Diabetes mellitus in dogs: relationship of obesity to glucose tolerance and insulin response. *Am J Vet Res* **45**, 98-103

M. Mattin, D. O'Neill, D. Church, P. D. McGreevy, P. C. Thomson & D. Brodbelt (2014) An epidemiological study of diabetes mellitus in dogs attending first opinion practice in the UK. *Vet Rec* **174**, 349

T. M. McCann, K. E. Simpson, D. J. Shaw, J. A. Butt & D. A. Gunn-Moore (2007) Feline diabetes mellitus in the UK: the prevalence within an insured cat population and a questionnaire-based putative risk factor analysis. *J Feline Med Surg* **9**, 289-299

J. M. Meegan, I. F. Sidor, J. M. Steiner, D. Sarran & J. L. Dunn (2008) Chronic pancreatitis with secondary diabetes mellitus treated by use of insulin in an adult California sea lion. *J Am Vet Med Assoc* **232**, 1707-1712

Y. Miyamoto, T. Kamisawa, T. Tabata, S. Hara, S. Kuruma, K. Chiba, Y. Inaba, G. Kuwata, T. Fujiwara, H. Egashira, K. Koizumi, R. Sekiya, J. Fujiwara, T. Arakawa, K. Momma & T. Asano (2012) Short and long-term outcomes of diabetes mellitus in patients with autoimmune pancreatitis after steroid therapy. *Gut Liver* **6**, 501-504

R. Neiger, A. L. Witt, A. Noble & A. J. German (2004) Trilostane therapy for treatment of pituitary-dependent hyperadrenocorticism in 5 cats. *J Vet Intern Med* **18**, 160-164

S. J. Newman, J. M. Steiner, K. Woosley, D. A. Williams & L. Barton (2006) Histologic assessment and grading of the exocrine pancreas in the dog. *J Vet Diagn Invest* **18**, 115-118

S. J. Niessen (2010) Feline acromegaly: an essential differential diagnosis for the difficult diabetic. *J Feline Med Surg* **12**, 15-23

T. D. O'Brien (2002) Pathogenesis of feline diabetes mellitus. *Mol Cell Endocrinol* **197**, 213-219

S. O'Neill, K. Drobatz, E. Satyaraj & R. Hess (2012) Evaluation of cytokines and hormones in dogs before and after treatment of diabetic ketoacidosis and in uncomplicated diabetes mellitus. *Vet Immunol Immunopathol* **148**, 276-283

E. L. Opie (1901) On the Relation of Chronic Interstitial Pancreatitis to the Islands of Langerhans and to Diabetes Melutus. *J Exp Med* **5**, 397-428

M. Osto, E. Zini, C. E. Reusch & T. A. Lutz (2012) Diabetes from humans to cats. *Gen Comp Endocrinol* **182C**, 48-53

K. Papa, A. Mathe, Z. Abonyi-Toth, A. Sterczer, R. Psader, C. Hetyey, P. Vajdovich & K. Voros (2011) Occurrence, clinical features and outcome of canine pancreatitis (80 cases). *Acta Vet Hung* **59**, 37-52

P. Pavan Kumar, G. Radhika, G. V. Rao, R. Pradeep, C. Subramanyam, R. Talukdar, D. N. Reddy & M. Sasikala (2012) Interferon gamma and glycemic status in diabetes associated with chronic pancreatitis. *Pancreatology* **12**, 65-70

A. G. Poppl, T. S. Mottin & F. H. Gonzalez (2012) Diabetes mellitus remission after resolution of inflammatory and progesterone-related conditions in bitches. *Res Vet Sci*

A. Prahl, L. Guptill, N. W. Glickman, M. Tetrick & L. T. Glickman (2007) Time trends and risk factors for diabetes mellitus in cats presented to veterinary teaching hospitals. *J Feline Med Surg* **9**, 351-358

V. S. Raman, R. W. Loar, V. S. Renukuntla, K. V. Hassan, D. S. Fishman, M. A. Gilger & R. A. Heptulla (2011) Hyperglycemia and diabetes mellitus in children with pancreatitis. *J Pediatr* **158**, 612-616 e611

J. Rand (1999) Current understanding of feline diabetes: part 1, pathogenesis. *J Feline Med Surg* **1**, 143-153

J. S. Rand, L. M. Fleeman, H. A. Farrow, D. J. Appleton & R. Lederer (2004) Canine and feline diabetes mellitus: nature or nurture? *J Nutr* **134**, 2072S-2080S

J. S. Rand & R. D. Marshall (2005) Diabetes mellitus in cats. *Vet Clin North Am Small Anim Pract* **35**, 211-224

H. Rinderknecht (1986) Activation of pancreatic zymogens. Normal activation, premature intrapancreatic activation, protective mechanisms against inappropriate activation. *Dig Dis Sci* **31**, 314-321

C. G. Ruaux & R. B. Atwell (1998) A severity score for spontaneous canine acute pancreatitis. *Aust Vet J* **76**, 804-808

M. Sasikala, R. Talukdar, P. Pavan kumar, G. Radhika, G. V. Rao, R. Pradeep, C. Subramanyam & D. Nageshwar Reddy (2012) beta-Cell dysfunction in chronic pancreatitis. *Dig Dis Sci* **57**, 1764-1772

S. W. Schmid, W. Uhl, H. Friess, P. Malfertheiner & M. W. Buchler (1999) The role of infection in acute pancreatitis. *Gut* **45**, 311-316

P. J. Selman, J. A. Mol, G. R. Rutteman, E. van Garderen & A. Rijnberk (1994) Progestin-induced growth hormone excess in the dog originates in the mammary gland. *Endocrinology* **134**, 287-292

H. N. Shen, Y. H. Chang, H. F. Chen, C. L. Lu & C. Y. Li (2012) Increased risk of severe acute pancreatitis in patients with diabetes. *Diabet Med* **29**, 1419-1424
S. E. Shoelson & A. B. Goldfine (2009) Getting away from glucose: fanning the flames of obesity-induced inflammation. *Nat Med* **15**, 373-374
S. E. Shoelson, L. Herrero & A. Naaz (2007) Obesity, inflammation, and insulin resistance. *Gastroenterology* **132**, 2169-2180
S. E. Shoelson, J. Lee & A. B. Goldfine (2006) Inflammation and insulin resistance. *J Clin Invest* **116**, 1793-1801
A. D. Short, B. Catchpole, L. J. Kennedy, A. Barnes, A. C. Lee, C. A. Jones, N. Fretwell & W. E. Ollier (2009) T cell cytokine gene polymorphisms in canine diabetes mellitus. *Vet Immunol Immunopathol* **128**, 137-146
N. Singh, P. Bhardwaj, R. M. Pandey & A. Saraya (2012) Oxidative stress and antioxidant capacity in patients with chronic pancreatitis with and without diabetes mellitus. *Indian J Gastroenterol* **31**, 226-231
L. I. Slingerland, V. V. Fazilova, E. A. Plantinga, H. S. Kooistra & A. C. Beynen (2009) Indoor confinement and physical inactivity rather than the proportion of dry food are risk factors in the development of feline type 2 diabetes mellitus. *Vet J* **179**, 247-253
N. S. Solanki, S. G. Barreto & G. T. Saccone (2012) Acute pancreatitis due to diabetes: the role of hyperglycaemia and insulin resistance. *Pancreatology* **12**, 234-239
J. M. Steiner & D. A. Williams (1999) Feline exocrine pancreatic disorders. *Vet Clin North Am Small Anim Pract* **29**, 551-575
W. Tsuang, U. Navaneethan, L. Ruiz, J. B. Palascak & A. Gelrud (2009) Hypertriglyceridemic pancreatitis: presentation and management. *Am J Gastroenterol* **104**, 984-991
A. Tvarijonaviciute, J. J. Ceron, S. L. Holden, D. J. Cuthbertson, V. Biourge, P. J. Morris & A. J. German (2012) Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome. *BMC Vet Res* **8**, 147
K. R. Verkest, L. M. Fleeman, J. M. Morton, S. J. Groen, J. S. Suchodolski, J. M. Steiner & J. S. Rand (2012) Association of postprandial serum triglyceride concentration and serum canine pancreatic lipase immunoreactivity in overweight and obese dogs. *J Vet Intern Med* **26**, 46-53
R. J. Washabau (2001) Feline acute pancreatitis--important species differences. *J Feline Med Surg* **3**, 95-98
P. Watson (2012) Chronic pancreatitis in dogs. *Top Companion Anim Med* **27**, 133-139
P. J. Watson (2003) Exocrine pancreatic insufficiency as an end stage of pancreatitis in four dogs. *J Small Anim Pract* **44**, 306-312
P. J. Watson, J. Archer, A. J. Roulois, T. J. Scase & M. E. Herrtage (2010) Observational study of 14 cases of chronic pancreatitis in dogs. *Vet Rec* **167**, 968-976
P. J. Watson, A. J. Roulois, T. Scase, P. E. Johnston, H. Thompson & M. E. Herrtage (2007) Prevalence and breed distribution of chronic pancreatitis at post-mortem examination in first-opinion dogs. *J Small Anim Pract* **48**, 609-618
J. P. Whitehead, A. A. Richards, I. J. Hickman, G. A. Macdonald & J. B. Prins (2006) Adiponectin--a key adipokine in the metabolic syndrome. *Diabetes Obes Metab* **8**, 264-280
A. J. Williams, S. L. Thrower, I. M. Sequeiros, A. Ward, A. S. Bickerton, J. M. Triay, M. P. Callaway & C. M. Dayan (2012) Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. *J Clin Endocrinol Metab* **97**, E2109-2113
P. G. Xenoulis & J. M. Steiner (2008) Current concepts in feline pancreatitis. *Top Companion Anim Med* **23**, 185-192
P. G. Xenoulis, J. S. Suchodolski, C. G. Ruaux & J. M. Steiner (2010) Association between serum triglyceride and canine pancreatic lipase immunoreactivity concentrations in miniature schnauzers. *J Am Anim Hosp Assoc* **46**, 229-234
Y. Xue, Y. Sheng, H. Dai, H. Cao, Z. Liu & Z. Li (2012) Risk of development of acute pancreatitis with pre-existing diabetes: a meta-analysis. *Eur J Gastroenterol Hepatol* **24**, 1092-1098

L. Yang, Z. He, X. Tang & J. Liu (2013) Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. *Eur J Gastroenterol Hepatol* **25**, 225-231
D. Zechner, M. Spitzner, A. Bobrowski, N. Knapp, A. Kuhla & B. Vollmar (2012) Diabetes aggravates acute pancreatitis and inhibits pancreas regeneration in mice. *Diabetologia* **55**, 1526-1534
E. Zini, M. Hafner, M. Osto, M. Franchini, M. Ackermann, T. A. Lutz & C. E. Reusch (2010a) Predictors of clinical remission in cats with diabetes mellitus. *J Vet Intern Med* **24**, 1314-1321
E. Zini, M. Osto, M. Franchini, F. Guscetti, M. Y. Donath, A. Perren, R. S. Heller, P. Linscheid, M. Bouwman, M. Ackermann, T. A. Lutz & C. E. Reusch (2009) Hyperglycaemia but not hyperlipidaemia causes beta cell dysfunction and beta cell loss in the domestic cat. *Diabetologia* **52**, 336-346
E. Zini, M. Osto, S. Moretti, M. Franchini, P. H. Kook, H. Lutz, F. Guscetti, A. Perren, L. E. Hoelzle, M. Ackermann, T. A. Lutz & C. E. Reusch (2010b) Hyperglycaemia but not hyperlipidaemia decreases serum amylase and increases neutrophils in the exocrine pancreas of cats. *Res Vet Sci* **89**, 20-26

Table 1

Classification of canine diabetes mellitus (Catchpole and others 2005)

Insulin deficiency diabetes (IDD)

Primary IDD in dogs is characterised by a progressive loss of pancreatic beta cells. The aetiology of beta cell deficiency/destruction in diabetic dogs is currently unknown but a number of diseases processes are thought to be involved:

- Congenital beta cell hypoplasia/abiotrophy
- Beta cell loss associated with exocrine pancreatic disease
- Immune-mediated beta cell destruction
- Idiopathic

Insulin resistance diabetes (IRD)

Primary IRD usually results from antagonism of insulin function by other hormones:

- Dioestrous/gestational diabetes
- Secondary to other endocrine disorders
- Hyperadrenocorticism
- Acromegaly
- Iatrogenic
- Synthetic glucocorticoids
- Synthetic progestagens
- Glucose intolerance associated with obesity might contribute to insulin resistance but is not a primary cause of diabetes in dogs

Figure 1 – The putative influences of diabetes on pancreatitis and vice versa